2021 Section 1 - This Class is full, please click here to see other upcoming classes.
Dr. Ingmar Gorman*, Fluence Co-Founder and Lead Trainer
Andrew Rose, Fluence Assistant Trainer
Dr. Eduardo Schenberg & Dr. Alan K Davis
Fridays: 9:30-11AM US Eastern Time/New York ((EST through March 13, EDT starting March 14th)
1/8, 1/15, 1/22, 1/29, 2/5, 2/12, 2/19, 2/26, 3/5, 3/12, 3,19, 3/26
$1,200 for 12-sessions
Optional CE certificate for $65
To obtain your certificate, the CE form must be filled out within 14 days of class completion.
This Class is full, please click here to see other upcoming classes.
This course can be taken in partial fulfillment of the requirements for the Fluence Postgraduate Certificate in Psychedelic Integration Therapy or Ketamine-assisted Psychotherapy.
This reading and study group will meet weekly for 12 weeks, and maintain the same membership for the 12 week period. The group will have a syllabus with papers or chapters that participants are expected to read. The format will include a short review of a selected paper by the group leader, followed by discussion of the content and related matters. This group will not be a forum for case presentations or extended sharing, either personal or clinical. The group is open to all, but will assume that members are interested in studying the academic literature on psychedelics from clinical, psychological, anthropological and philosophical points of view. We are asking Reading Group members to commit to the full 12-week series upon registration.
*Andrew Rose will be the lead faculty and will be present for all live-online course sessions. Ingmar Gorman will be present for live-online three course sessions and available to course participants through the discussion board throughout the course. Guest teachers will each be present at one session each to discuss their work with course participants.
About our Guest Teachers:
Dr. Alan K Davis is an Assistant Professor of Social Work at The Ohio State University and Adjunct Assistant Professor in the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Dr. Davis’s clinical experience includes working with people diagnosed with trauma-based psychological problems such as addiction, PTSD, depression, and anxiety. His clinical expertise includes providing evidenced-based treatments such as motivational interviewing, cognitive behavioral therapy, acceptance and commitment therapy, and psilocybin-assisted psychotherapy. Consistent with his clinical interests, his research interests and expertise focus on contributing to the knowledge of and ability to help those suffering with substance use and mental health problems, understanding how to improve clinical outcomes through examining new treatments, and developing ways to conceptualize substance use and mental health problems through a strengths-based approach. He recently completed a clinical trial of psilocybin therapy for major depressive disorder and current trials include exploring this treatment for patients with co-occurring alcohol use disorder and depression and patients with anorexia. He actively explores topics related to naturalistic psychedelic use among several populations including people of color who have experienced racial trauma, Spanish-speaking people, and people who use novel psychedelics such as 5-MeO-DMT.
Eduardo E. Schenberg has a PhD in neuroscience and a solid academic trajectory. He graduated and completed a Masters at the Federal University of São Paulo, obtained his PhD at the the University of São Paulo, and completed post-doc research at UNIFESP and Imperial College London. He received honorary awards from the Brazilian Society for Neuroscience and the European Brain and Behavior Society, besides multiple grants from the International Brain Research Organization. He specialized in psychoactive drugs and their varied effects--harmful as well as therapeutic--with focus on psychedelic substances (ayahuasca, LSD, ibogaine, MDMA, and psilocybin, among others). He conducted and participated in groundbreaking research, including an EEG study about ayahuasca and the first neuroimaging study of LSD, with more than 300 citations. Since then his focus has been the promising therapeutic applications of psychedelics to treat addiction, PTSD, depression and other conditions. In 2018 he published a perspective in Frontiers in Pharmacology which is close to 70 thousand views, arguing that psychedelic-assisted psychotherapy (PAP) represents a paradigm shift in psychiatric research and development. He was also the PI in the first psychedelic-assisted psychotherapy research in the history of Brazil, obtaining permissions from health authorities such as ANVISA and CONEP to use MDMA to treat PTSD, published in 2020 in the Brazilian Journal of Psychiatry and covered at Folha de São Paulo, Brazil’s most respected daily journal, BBC Brasil and Marie Claire. In 2019 he received the prestigious Trip Transformadores award from Trip Magazine. He is the founder and Director of Instituto Phaneros, a non-profit currently with more than 400 students in courses about psychedelics in mental health.
At the end of the study group (RSG), the participant will be able to:
1. Describe and clinically recognize the emergence of increased interpersonal ”connectedness” as a central component of improvement from depressive disorders seen with psychedelic therapy
2. Use the direct subjective experiences reported by participants in psychedelic therapy to establish and maintain abstinence in individuals with addictive disorders
3. List the ways that psychedelic therapy helped individuals with cancer related anxiety regain meaning in their lives and recover from existential distress caused by their cancer diagnosis and treatment
4. Describe the components of psychological rigidity and psychological flexibility and list the ways that psilocybin therapy facilitates improvement in anxiety and depressive disorders
6. Critique the concept of creativity and microdosing of psychedelic medicines and describe how these medicines may be used to enhance creativity in the future.
7. Analyze a recent research study on psychedelic and creativity to explain the historic anecdotal reports in enhanced creativity through use of psychedelic experiences.
8. Compare indigenous concepts of ayahuasca cosmology with those found in contemporary neo-shamanism, and apply this knowledge to experiences that patients report in traditional psychotherapy settings
9. Revise traditional meanings of terms used in Western psychology (light, dark, healing, change, spirit) in accordance with ones that patients learn in their work in neoshamanic ayahuasca ceremonies
10. Prepare to understand the meaning of purging and vomiting during ayahuasca ceremonies in ways that are radically different from the meanings commonly used for those behaviors in Western psychology.
Information on Continuing Education Credit for Health Professionals
• CE credits for psychologists are provided by the Spiritual Competency Resource Center (SCRC) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content.
• The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association.
• LCSWs, MFTs, and other mental health professionals from states other than California need to check with their state licensing board as to whether or not they accept programs offered by approved sponsors of CE by the American Psychological Association.
• SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California.
• For questions about receiving your Certificate of Attendance, contact Elizabeth Nielson, firstname.lastname@example.org. For questions about CE, visit www.spiritualcompetency.com or contact David Lukoff, PhD at CE@spiritualcompetency.com.